364 related articles for article (PubMed ID: 26608958)
1. Immunohistochemical expression of cyclooxygenase-2 (COX-2) in oral nevi and melanoma.
de Souza do Nascimento J; Carlos R; Delgado-Azañero W; Mosqueda Taylor A; de Almeida OP; Romañach MJ; de Andrade BA
J Oral Pathol Med; 2016 Jul; 45(6):440-3. PubMed ID: 26608958
[TBL] [Abstract][Full Text] [Related]
2. Expression of fatty acid synthase (FASN) in oral nevi and melanoma.
de Andrade BA; León JE; Carlos R; Delgado-Azañero W; Mosqueda-Taylor A; Graner E; de Almeida OP
Oral Dis; 2011 Nov; 17(8):808-12. PubMed ID: 21819495
[TBL] [Abstract][Full Text] [Related]
3. COX-1 and COX-2 expression in canine cutaneous, oral and ocular melanocytic tumours.
Pires I; Garcia A; Prada J; Queiroga FL
J Comp Pathol; 2010; 143(2-3):142-9. PubMed ID: 20207364
[TBL] [Abstract][Full Text] [Related]
4. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
[TBL] [Abstract][Full Text] [Related]
5. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
6. Mast cells in melanocytic skin lesions. An immunohistochemical and quantitative study.
Dyduch G; Okoń K; Pescarini E
Pol J Pathol; 2011 Sep; 62(3):139-44. PubMed ID: 22102069
[TBL] [Abstract][Full Text] [Related]
7. Black and Brown Oro-facial Mucocutaneous Neoplasms.
Natarajan E
Head Neck Pathol; 2019 Mar; 13(1):56-70. PubMed ID: 30693458
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours.
Chwirot BW; Kuźbicki Ł
Melanoma Res; 2007 Jun; 17(3):139-45. PubMed ID: 17505259
[TBL] [Abstract][Full Text] [Related]
9. The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions.
Pilloni L; Bianco P; Difelice E; Cabras S; Castellanos ME; Atzori L; Ferreli C; Mulas P; Nemolato S; Faa G
Eur J Histochem; 2011 Jun; 55(2):e20. PubMed ID: 22193299
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression patterns of the microRNA-processing enzyme Dicer in cutaneous malignant melanomas, benign melanocytic nevi and dysplastic melanocytic nevi.
Sand M; Gambichler T; Sand D; Altmeyer P; Stuecker M; Bechara FG
Eur J Dermatol; 2011; 21(1):18-21. PubMed ID: 21262599
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of cyclooxygenage-2 in melanocytic skin lesions.
Minami S; Lum CA; Kitagawa KM; Namiki TS
Int J Dermatol; 2011 Jan; 50(1):24-9. PubMed ID: 21182498
[TBL] [Abstract][Full Text] [Related]
12. Fatty acid synthase expression in cutaneous melanocytic neoplasms.
Kapur P; Rakheja D; Roy LC; Hoang MP
Mod Pathol; 2005 Aug; 18(8):1107-12. PubMed ID: 15920554
[TBL] [Abstract][Full Text] [Related]
13. The value of cyclooxygenase-2 expression in differentiating between early melanomas and histopathologically difficult types of benign human skin lesions.
Kuźbicki Ł; Lange D; Strączyńska-Niemiec A; Chwirot BW
Melanoma Res; 2012 Feb; 22(1):70-6. PubMed ID: 22228276
[TBL] [Abstract][Full Text] [Related]
14. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
15. Expression of cyclo-oxygenase-2 in macrophages associated with cutaneous melanoma at different stages of progression.
Bianchini F; Massi D; Marconi C; Franchi A; Baroni G; Santucci M; Mannini A; Mugnai G; Calorini L
Prostaglandins Other Lipid Mediat; 2007 Jun; 83(4):320-8. PubMed ID: 17499752
[TBL] [Abstract][Full Text] [Related]
16. Proliferative activity of primary cutaneous melanocytic tumours.
Kuwata T; Kitagawa M; Kasuga T
Virchows Arch A Pathol Anat Histopathol; 1993; 423(5):359-64. PubMed ID: 7906909
[TBL] [Abstract][Full Text] [Related]
17. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
Bahmad HF; Oh KS; Alexis J
J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
[TBL] [Abstract][Full Text] [Related]
18. MSG-1 expression in benign and malignant melanocytic lesions of cutaneous and mucosal epithelium.
Sedghizadeh PP; Williams JD; Allen CM; Prasad ML
Med Sci Monit; 2005 Jul; 11(7):BR189-94. PubMed ID: 15990678
[TBL] [Abstract][Full Text] [Related]
19. Melanomas Associated With Blue Nevi or Mimicking Cellular Blue Nevi: Clinical, Pathologic, and Molecular Study of 11 Cases Displaying a High Frequency of GNA11 Mutations, BAP1 Expression Loss, and a Predilection for the Scalp.
Costa S; Byrne M; Pissaloux D; Haddad V; Paindavoine S; Thomas L; Aubin F; Lesimple T; Grange F; Bonniaud B; Mortier L; Mateus C; Dreno B; Balme B; Vergier B; de la Fouchardiere A
Am J Surg Pathol; 2016 Mar; 40(3):368-77. PubMed ID: 26645730
[TBL] [Abstract][Full Text] [Related]
20. Different patterns of expression of the erbB family of receptor tyrosine kinases in common nevi, dysplastic nevi, and primary malignant melanomas: an immunohistochemical study.
Feinmesser M; Veltman V; Morgenstern S; Tobar A; Gutman H; Kaganovsky E; Tzabari C; Sulkes J; Okon E
Am J Dermatopathol; 2010 Oct; 32(7):665-75. PubMed ID: 20559114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
